Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose co-transporter-2 inhibitor (SGLT-2i)…
- Trial name
- SUSTAIN 9 (NCT03086330)
- Testing
- Semaglutide
- Where
- 72 sites in United States, Austria and 5 more
- Volunteers
- 302 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled…
- Trial name
- NCT00095030
- Testing
- muraglitazar
- Where
- 206 sites in United States, Argentina and 15 more
- Volunteers
- 1,752 people
- Sponsor
- Bristol-Myers Squibb
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy and safety of two different formulations of insulin degludec (IDeg) in subjects with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01364428)
- Testing
- insulin degludec
- Where
- 45 sites in United States
- Volunteers
- 373 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamic effects and pharmacokinetic characteristics of JNJ-28431754 after multiple dosing in patients with Type 2 Diabetes Mellitus who are on a stable…
- Trial name
- NCT01177163
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Glycemic Control
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy of 2 doses of TAK-875 (25 mg and 50 mg), once daily (QD), plus metformin compared to placebo plus metformin and sitagliptin plus metformin on lowering blood sugar.
- Trial name
- NCT01549964
- Testing
- Fasiglifam (TAK-875), Sitagliptin
- Where
- 160 sites in United States, Australia and 9 more
- Volunteers
- 916 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2, Healthy Males
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
26 subjects will be enrolled into 5 different dose groups. The trial will consist of a screening, a dosing and a follow-up visit.
- Trial name
- NCT00475371
- Testing
- MKC253 Inhalation Powder
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Diabetes, Diabetes Mellitus, Type 1
Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate steady state pharmacokinetics of biphasic insulin aspart 30 and biphasic insulin aspart 70 in subjects with type 1 diabetes.
- Trial name
- NCT01524809
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 70
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of XOMA 052 in subjects with stable Type 2 Diabetes Mellitus (T2D).
- Trial name
- NCT00513214
- Testing
- XOMA 052
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- XOMA (US) LLC
Type 2 Diabetes Mellitus
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when added to glimepiride on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are…
- Trial name
- NCT01494987
- Testing
- Ranolazine, Glimepiride, Diet
- Where
- 140 sites in United States, Czechia and 10 more
- Volunteers
- 431 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
- Trial name
- NCT00838916
- Testing
- albiglutide, insulin glargine
- Where
- 337 sites in United States, Russia and 2 more
- Volunteers
- 779 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive…
- Trial name
- NCT00614055
- Testing
- insulin degludec/insulin aspart, insulin glargine, metformin
- Where
- 28 sites in France, Germany and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Ketosis Prone Diabetes, Diabetes Ketoacidosis
Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment
The study intends on enrolling 48 subjects with diabetes. Diabetic subjects that no longer need insulin will be randomly placed (like the flip of a coin) on a diabetes pill called metformin, a diabetes pill called sitagliptin or…
- Conditions
- Ketosis Prone Diabetes, Diabetes Ketoacidosis, Hyperglycemia
- Trial name
- NCT01099618
- Testing
- metformin, Sitagliptin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dawn Smiley MD
Periodontal Diseases
Quantification of CD163 Inflammatory Biomarker in Chronic Periodontitis and Diabetic Subjects
The quantification of CD163 will be analysed in the subgingival plaque samples of generalized chronic periodontitis patients with and without diabetes mellitus.
- Trial name
- NCT03727035
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Meenakshi Ammal Dental College and Hospital
Obesity, Adiposity
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake
We aim to delineate the effects of separate and combined infusion of GIP and GLP-1 on food intake, appetite, bone health and fat metabolism in overweight/obese subjects.
- Conditions
- Obesity, Adiposity, Type 2 Diabetes
- Trial name
- GASOLIN (NCT02598791)
- Testing
- IIGI+GIP, IIGI+GLP-1, OGTT
- Where
- Denmark
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes.
- Trial name
- NCT00263276
- Testing
- dapagliflozin, metformin
- Where
- 144 sites in United States, Canada and 2 more
- Volunteers
- 389 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in…
- Trial name
- NCT01733758
- Testing
- Albiglutide 30 mg weekly, Albiglutide 50 mg weekly, Liraglutide 0.9 mg daily
- Where
- 74 sites in Japan
- Volunteers
- 494 people
- Sponsor
- GlaxoSmithKline
Diabetes, Type 2
Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months.
- Trial name
- NCT01336738
- Testing
- 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532
- Where
- 44 sites in United States, Canada and 5 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
- Trial name
- NCT01285518
- Testing
- PF-05231023
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Diabetes Mellitus
Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus
The Phase 1b study is a multi-center trial designed to test the safety, tolerability, biologic activity of escalating doses of FG-3019 in up to 20 patients with type 1 or type 2 diabetes and microalbuminuria (early-stage kidney…
- Trial name
- NCT00102297
- Testing
- FG-3019
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Kyntra Bio
Diabetes Mellitus, Type 2
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
The purpose of the study is to determine the effect of glimepiride on dapagliflozin and the effect of dapagliflozin on glimepiride in healthy volunteers.
- Trial name
- NCT00562250
- Testing
- Dapagliflozin, Glimepiride, Dapagliflozin + Glimepiride
- Where
- Argentina
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.